业界动态监管公开信息 · FDA
FDA授予mirvetuximab soravtansine-gynx加速批准，用于FRα阳性、铂耐药的上皮性卵巢癌、输卵管癌或腹膜癌
FDA Drugs · 2026-11-10 05:53
摘要
FDA授予mirvetuximab soravtansine-gynx加速批准，用于FRα阳性、铂耐药的上皮性卵巢癌、输卵管癌或腹膜癌
English
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer